Lexeo Therapeutics

Lexeo Therapeutics is a clinical-stage genetic medicine company that seeks to transform healthcare by applying groundbreaking science to fundamentally change the way diseases are treated.

The company's lead products are drugs targeting cardiovascular disease and Alzheimer's disease.

Lexeo Therapeutics has filed for a $100 million IPO. The company plans to use the funds raised to further develop treatments for cardiovascular disease and Alzheimer's disease
__________________________________
Number of employees:
50 - 100
________________________________
Headquarters:
345 Park Avenue South, Floor 6 New York, NY 10010